Read More

Atara Biotherapeutics Submits Tabelecleucel BLA For Treatment Of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease With U.S. FDA; Acceptance Of BLA Will Trigger $20M Milestone Payment From Pierre Fabre Laboratories, With Potential…

First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug AdministrationIf Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLDAcceptance of BLA Will Trigger $20 Million Milestone Payment